Dexcom vs ResMed|
ResMed| is the larger business, with $5.65bn of revenue in fiscal 2026 against $4.66bn for Dexcom (1.2 times as much). Dexcom grew faster (15.6% against 9.9%). ResMed| kept more of each dollar of sales as profit: a net margin of 26.9% against 17.9%.
| Latest fiscal year | DexcomDXCM, 2025 | ResMed|RMD, 2026 |
|---|---|---|
| Revenue | $4.66bn | $5.65bn |
| Revenue growth | 15.6% | 9.9% |
| Net income | $836m | $1.52bn |
| Operating margin | 19.6% | — |
| Net margin | 17.9% | 26.9% |
| Return on equity | 34.5% | 24.3% |
| Free cash flow | $1.08bn | $1.65bn |
| Cash | $918m | $1.47bn |
| Total debt | $1.24bn | $659m |
| Debt to equity | 45.2% | — |
| Dividend per share | — | $2.40 |
| Dividend yield | — | 1.1% |
| Share buybacks | $500m | $700m |
| Employees | 11,100 | 11,370 |
| Market value | $31.01bn | $31.58bn |
| Price vs our value range | Within our value range | Within our value range |
| Moat score | 56 (Moderate) | 88 (Strong) |
| Insider trades, 12 months | 2 buys, 32 sales | 0 buys, 32 sales |